PPARG and steatosis: In fact, treatment of obese and diabetic mice with the selective PPARγ activator thiazolidinediones has been reported to result in centrilobular steatosis in the liver [55], and disruption of PPARγ in ob/ob mice has been shown to be beneficial to the liver [56].